An anonymous director reports

APTOSE BIOSCIENCES MEETS NASDAQ MINIMUM BID PRICE COMPLIANCE

Aptose Biosciences Inc. today received a written notification from the listing qualifications department of The Nasdaq Stock Market LLC notifying the company that it meets compliance with the Nasdaq's minimum bid price requirement.

In July, 2022, Aptose received notice from Nasdaq that its common shares failed to maintain a minimum bid price to remain listed on the exchange. Aptose was allowed a cure period of six months, along with an additional six-month extension period, to meet the minimum share price or greater. As a mechanism for cure and supported by shareholder approval, Aptose implemented a reverse stock split during June, 2023. On June 21, 2023, Nasdaq confirmed that, for 10 consecutive business days, the closing bid price of the company's common stock has been at $1.00 per share or greater. Accordingly, the company meets compliance with Listing Rule 5550(a(2), and the matter is closed.

About Aptose Biosciences Inc.

Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The company's small-molecule cancer therapeutics pipeline includes products designed to provide single-agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: tuspetinib (HM43239), an oral, myeloid kinase inhibitor being studied as monotherapy and in combination therapy in the Aptivate international phase 1/2 expansion trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib (CG-806), an oral, dual lymphoid and myeloid kinase inhibitor in phase 1 a/b stage development for the treatment of patients with relapsed or refractory hematologic malignancies.

We seek Safe Harbor.